Infectious Disease Diagnostics – Products

PCR Biosystems are continuing to scale up operations to ensure the critical enzyme mix for COVID-19 tests remain available to the UK and global healthcare systems as demand for testing rises.

MicrosensDx has announced that the test for research use in the detection of RNA from the SARS-Cov-2 virus in sputum, throat and nose swabs has now been assessed for clinical performance

Wales’ leading organization for healthcare innovation is calling on companies and innovators from across the country to join the fight against coronavirus.

Luminex Corporation has announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its NxTAG® CoV Extended Panel.

FDA grants emergency use authorization for fastest available molecular point-of-care test for novel coronavirus.

The Anti-SARS-CoV-2 ELISAs for immunoglobulin classes A and G from EUROIMMUN, a PerkinElmer, Inc. company, have received the CE mark and can now be applied to COVID-19 diagnostics.

SOPHiA GENETICS has announced that it is entering the fight against the COVID-19 coronavirus by extending its partnership with Paragon Genomics, who developed a next-generation sequencing (NGS) assay and leveraging the SOPHiA Platform analytical capabilities, as well as delivering the benefits of this solution to its install base of over 1,000 hospitals worldwide in the next weeks.

Mologic Ltd has announced that it has initiated early validation of COVID-19 point-of-need diagnostic tests with the Liverpool School of Tropical Medicine and St Georges’ University London.

Scientists say early data, generated with new NGS research panel from Thermo Fisher Scientific, suggest coronavirus is genetically stable and could increase the effectiveness of vaccines in development.

PerkinElmer has announced that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the company’s new Coronavirus RT-PCR test.